Cargando…
Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption
A 67-year-old woman with a history of end-stage renal disease on hemodialysis received a therapeutic dose (150 mg daily) of flecainide for three weeks. She was admitted to the Emergency Department for malaise and dizziness, and the electrocardiogram revealed ventricular tachycardia treated by amioda...
Autores principales: | De Schryver, Nicolas, Hantson, Philippe, Haufroid, Vincent, Dechamps, Mélanie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681578/ https://www.ncbi.nlm.nih.gov/pubmed/31428479 http://dx.doi.org/10.1155/2019/1905871 |
Ejemplares similares
-
Experience with hemoadsorption (CytoSorb(®)) in the management of septic shock patients
por: Mehta, Yatin, et al.
Publicado: (2020) -
Hemoadsorption by CytoSorb in septic patients: a case series
por: Kogelmann, Klaus, et al.
Publicado: (2017) -
Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption
por: Schneider, Antoine G., et al.
Publicado: (2021) -
Hemoadsorption in the critically ill—Final results of the International CytoSorb Registry
por: Hawchar, Fatime, et al.
Publicado: (2022) -
Sublingual Microcirculatory Evaluation of Extracorporeal Hemoadsorption with CytoSorb® in Abdominal Sepsis: A Case Report
por: Duran, Servet, et al.
Publicado: (2022)